Conagen Produces Two Thaumatin Protein Natural Sweeteners at Scale

100,000 times sweeter than table sugar

Bedford, Mass., March 23, 2022 (GLOBE NEWSWIRE) — Food and beverages brands get two more tools for their sugar reduction toolkits as Conagen announced the successful scale-up production of two new high-intensity sweeteners, thaumatin I and thaumatin II. The development will expand commercial partner Sweegen’s robust sugar reduction solutions of zero-sugar natural sweeteners.

Thaumatin is a group of proteins found in the fruits of the tropical plant Thaumatococcus danielli. Each protein, thaumatin I and thaumatin II, varies slightly in sweetness profiles. Both proteins have been evaluated as 100,000 times sweeter than sugar on a molar basis and 3,000 times sweeter on a weight basis. The high sweetness factor can translate into a strategic cost-effective sugar reduction solution for brands seeking to get the most out of a natural sweetener.

The thaumatin proteins were developed from Conagen’s peptide production platform, which had previously been used for the scaled production of another peptide sweetener, brazzein. “Conagen constantly improves its protein and peptide production platforms to generate more exciting new products,” said Casey Lippmeier, vice president of innovation at Conagen. “In this case, the platform has been leveraged to make thaumatin by several innovative approaches, but under a significantly shorter R&D timeline.”

These two new, high-purity thaumatin proteins add to Sweegen’s creative portfolio of sugar reduction solutions to help brands make low-calorie products. Brands can now explore the synergistic benefits of formulations that contain thaumatin and other products from Sweegen’s Signature Sweetener portfolio, including brazzein and stevia. This diversity of natural, high-intensity sweeteners represents the most cost-effective approach for reducing sugar in food and beverages to deliver the best tasting match for the sweetness of sugar.

The desire for natural sweeteners will drive the demand for fruit and plant-based sweeteners, such as thaumatin and stevia, respectively. The main advantages to sweetening food and beverages with thaumatin are its familiarity and acceptance by consumers and the fact that it is approved for use in products by the majority of the countries in the world.

Health-conscious consumers are generally more accepting of natural sweeteners than sugar and artificial sweeteners. According to FMCG Gurus, Top 10 Future Trends 2030, “60% of global consumers currently believe natural sweeteners are healthier alternatives to sugar.” The trend report further stated, “Increasingly, consumers will want only products that contain real and authentic ingredients, and sweeteners will be no exception to the rule. As such, this will drive demand for sweeteners sourced directly from fruits and plants, something that the industry will respond to.”

Like most other proteins, when thaumatin proteins are consumed, they are digested into amino acids.  However, because thaumatin communicates such a strong sweet taste, the levels used in most applications contribute almost no calories. It is one of the most intense sweeteners ever discovered.

Consumers increasingly expect to stock their pantries with low-to-no sugar products with food and beverages that fit into their lifestyle and diets. Thaumatin can complement a number of consumer lifestyles, such as diabetic, ketogenic, or low-to-no carbohydrate diets. These sweet proteins are low on the glycemic index.

“Thaumatin is the second announced product generated from our peptide platform, which fits well into our existing world-scale, precision fermentation infrastructure.” Lippmeier further added, “Peptides and small proteins like brazzein and thaumatin can be very difficult to make economically; however, now that we have successfully scaled multiple peptides and proteins, we are willing to collaborate with other customers to make other novel peptide products.”

Regulatory approval for thaumatin as natural sweeteners has passed in the European Union (E957), Israel, and Japan. In the United States, it is generally recognized as safe as a flavoring agent (FEMA GRAS 3732).

About Conagen
Conagen is a product-focused, synthetic biology R&D company with large-scale manufacturing service capabilities. Our scientists and engineers use the latest synthetic biology tools to develop high-quality, sustainable, nature-based products by precision fermentation and enzymatic bioconversion. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. www.conagen.com

Attachment

Ana Arakelian, head of public relations and communications
Conagen
+1.781.271.1588
ana.arakelian@conagen.com

Keep Your Cool: Hisense Celebrates Closure of the Summer Season with New Hi-Season Campaign

CAPE TOWN, South Africa, March 22, 2022 /PRNewswire/ — As summer draws to a close in South Africa, Hisense, provider of high-performance TV and home appliances, is catching the last summer days to help the South African households keep their cool with its new Hi-Season campaign this March.

Any customers who purchase Hi-Season promotional products and send proof of purchase to prize@hisense.co.za before 15th April will enter the draw to win a Hisense fridge. Alongside the lucky draw, Hisense is offering savings up to R10,000 across its product range. It has be proof of purchase of an online purchase. Participating retailers include Takealot, Makro, Game, Hifi Corp, Everyshop, Hirsch, FNB Complete, and New World.

As part of the Hi-Season campaign, Hisense is casting the spotlight on three appliances that will help users reimagine summer:

75A6GS 4K UHD TV

Experience a total 4K solution with 4K resolution and an UHD AI Upscaler. Over 8 million pixels are housed for true 4K resolution, while the upscaler works to enhance non-4K signals to achieve near-4K resolution and greater detail than standard FHD signals. Feel immersed by the DTS virtual X advanced surround sound solution suite, or connect Bluetooth devices for more audio options. The 75A6GS also includes Game Mode and the VIDAA U4.0 personalized content platform for a non-stop summer of entertainment.

120L5F Laser TV

Bring the cinematic experience home with brighter pictures, natural colours and ultra-clear details. The ultra-short throw 120L5F Laser TV projects a colourful and bright image onto a 120-inch ambient light rejection screen that’s designed for viewing in any room in the house. Enjoy incredible image depth and quality with 4K UHD and over 8 million pixels — and with close to zero harmful blue lights, viewers benefit from a healthier viewing experience free from eye strain, even after long viewing periods.

H670SIA-WD Side by Side Refrigerator

H670SIA-WD is both energy efficient and environmentally friendly, earning the appliance an A+ energy class rating. Its multi-airflow technology cools the fridge evenly from corner to corner so food stays fresher for longer. Hisense’s frost-free technology reduces the humidity level to prevent frost formation, and the accelerated temperature adjustment ensures frozen goods defrost quickly. With the built-in internal water reservoir, users have a permanent supply of chilled water at the press of a button.

For more information on the Hi-season campaign, please visit https://hisense.co.za/ .

Photo – https://mma.prnewswire.com/media/1771531/HiSeason_Summer_KV___final.jpg

Moderna Says Its Low-Dose COVID Shots Work for Kids Under 6

Moderna’s COVID-19 vaccine works in babies, toddlers and preschoolers, the company announced Wednesday, a development that could pave the way for the littlest kids to be vaccinated by summer if regulators agree.

Moderna said that in the coming weeks it would ask regulators in the U.S. and Europe to authorize two small-dose shots for children younger than 6. The company also is seeking to have larger doses cleared for older children and teens in the U.S.

The announcement is positive news for parents who have anxiously awaited protection for younger tots and been continuously disappointed by setbacks and confusion over which shots might work and when. The nation’s 18 million children younger than 5 are the only age group not yet eligible for vaccination.

Moderna says early study results show tots develop high levels of virus-fighting antibodies from shots containing a quarter of the dose given to adults. Once Moderna submits its full data, the U.S. Food and Drug Administration will have to determine if that important marker means the youngsters are as protected against severe illness as adults.

“The vaccine provides the same level of protection against COVID in young kids as it does in adults. We think that’s good news,” Dr. Stephen Hoge, Moderna’s president, told The Associated Press.

But that key antibody finding isn’t the whole story. COVID-19 vaccines aren’t as effective against the super-contagious omicron mutant — in people of any age — and Moderna’s study found the same trend. There were no severe illnesses during the trial, but the vaccine was only about 44% effective at preventing milder infections in babies up to age 2, and nearly 38% effective in the preschoolers.

“Not a home run” but the shots still could be helpful for the youngest children, said Dr. Jesse Goodman of Georgetown University, a former FDA vaccine chief. Goodman said the high antibody levels seen in the study “should translate into higher efficacy against severe infections.”

Some parents say even a little protection would be better than leaving their youngest children unvaccinated.

“I don’t care if it’s even 15 or 20%,” said Lauren Felitti of Gaithersburg, Maryland. Her 4-year-old son Aiden, who’s at extra risk because of a heart condition, was hospitalized for eight days with COVID-19 and she’s eager to vaccinate him to lessen the chance of a reinfection.

“It was very scary,” Felitti said. “If there’s a chance that I’m able to keep him protected, even if it’s a small chance, then I’m all for it.”

Competitor Pfizer currently offers kid-size doses for school-age children and full-strength shots for those 12 and older. And the company is testing even smaller doses for children younger than 5 but had to add a third shot to its study when two didn’t prove strong enough. Those results are expected by early April.

If the FDA eventually authorizes vaccinations for little kids from either company, there still would be another hurdle. The Centers for Disease Control and Prevention recommends who should get them — and Goodman said there may be debate about shots for higher-risk children or everyone younger than 5.

Vaccinating the littlest “has been somewhat of a moving target over the last couple of months,” Dr. Bill Muller of Northwestern University, who is helping study Moderna’s pediatric doses, said in an interview before the company released its findings. “There’s still, I think, a lingering urgency to try to get that done as soon as possible.”

While COVID-19 generally isn’t as dangerous to youngsters as to adults, some do become severely ill. The CDC says about 400 children younger than 5 have died from COVID-19 since the pandemic’s start. The omicron variant hit children especially hard, with those under 5 hospitalized at higher rates than at the peak of the previous delta surge.

The younger the child, the smaller the dose being tested. Moderna enrolled about 6,900 kids under 6 — including babies as young as 6 months — in a study of the 25-microgram doses.

While the study wasn’t large enough to detect very rare side effects, Moderna said the small doses were safe and that mild fevers, like those associated with other common pediatric vaccines, were the main reaction.

Hudson Diener, 3, only briefly cried when getting test doses at Stony Brook Medicine in Commack, New York. His parents welcomed the study results and hope to learn that Hudson received the vaccine and not dummy shots.

“We are really hoping to get the answer we’re looking for soon so we can take a deep breath,” said Hudson’s mom, Ilana Diener. Wednesday’s news should “hopefully be a step closer for his age group to be eligible for the vaccine very soon.”

Boosters have proved crucial for adults to fight omicron, and Moderna currntly is testing those doses for children as well — either a third shot of the original vaccine or an extra dose that combines protection against the original virus and the omicron variant.

Parents may find it confusing that Moderna is seeking to vaccinate the youngest children before it’s cleared to vaccinate teens. While other countries have allowed Moderna’s shots to be used in children as young as 6, the U.S. has limited its vaccine to adults.

The FDA hasn’t ruled on Moderna’s earlier request to expand its shots to 12- to 17-year-olds because of concern about a very rare side effect. Heart inflammation sometimes occurs in teens and young adults, mostly males, after receiving either the Pfizer or Moderna vaccines. Moderna is getting extra scrutiny because its shots are a far higher dose than Pfizer’s.

The company said Wednesday that, armed with additional evidence, it is updating its FDA application for teen shots and requesting a green light for 6- to 11-year-olds, too. Hoge said he’s optimistic the company will be able to offer its vaccine “across all age groups in the United States by the summer.”

Moderna says its original adult dose — two 100-microgram shots — is safe and effective in 12- to 17-year-olds. For elementary school-age kids, it’s using half the adult dose.

About 1.5 million adolescents have used the Moderna vaccine in other countries, “and so far we’ve seen very reassuring safety from that experience,” Hoge said.

The heart risk also seems linked to puberty, and regulators in Canada, Europe and elsewhere recently expanded Moderna vaccinations to kids as young as 6.

“That concern has not been seen in the younger children,” said Northwestern’s Muller.

Source: Voice of America

Ukraine War Pushing Food Prices Even Higher

The world is feeling the effects of the war in Ukraine from the gas pump all the way to the dinner table.

Food prices are climbing just about everywhere, raising the risk of civil unrest, especially in countries dependent on imported wheat from Russia and Ukraine. That includes much of the Middle East and North Africa.

Experts say the food price increases are happening at an especially bad time.

“It’s kind of a perfect storm,” said Cornell University economics professor Chris Barrett. “It’s not just a matter of, food prices are going high. It’s food prices are going high at a moment when many places are already crippled by the challenges posed by COVID, by political disruptions elsewhere, by droughts and floods and other natural disasters.”

“And there’s only so much that people can take before they grow displeased with their political leadership if it’s failing to take care of them,” he added. “So, unrest is, unfortunately, increasingly likely right now.”

Conflict worsens inflation

Russia is the world’s leading wheat exporter. Ukraine is number five. Together, they grow up to a third of the world’s wheat exports.

But when war broke out, the Black Sea became a combat zone. Some cargo ships took fire. It didn’t take sanctions to cut off exports.

“There wasn’t a ban on grain trade, but in effect the ports were closed. And so shipment has stopped,” said Texas A&M University economist Mark Welch.

“Countries that import from Ukraine and Russia have suddenly found their contracts canceled and they’re not getting food shipments they were expecting, which forces them into the market to pay a premium to replace food shipments that just aren’t going to arrive,” Barrett said. “And that bids up the price of food around the world.”

But food prices have been rising for almost two years.

Bad weather cut harvests in some of the world’s breadbaskets. Reserves are low.

That’s helped push prices to record highs even before the conflict started.

“We’ve tipped over that edge where every change, every little thing, has a very large impact,” University of Illinois economist Joe Janzen said.

More problems coming

Now, Ukraine’s next harvest is in doubt. Farmers should be getting ready for the next growing season. But that’s hard to do right now.

“Logistical lines are obviously heavily disrupted right now,” Barrett said. “Seeds aren’t arriving. Fuel isn’t arriving. Fertilizer isn’t arriving.”

Russia’s farmers are getting hit, too. They’re not under sanctions. But Russia’s banks are. That basically shuts Russian farmers out of the financial system.

“We’re not going to say, ‘You can’t ship grain,'” Welch said. “But will they ship it if they can’t get paid?”

Then there’s the sharp increase in energy prices that makes shipping everything more expensive.

Also, natural gas is a main ingredient in fertilizers commonly used to boost grain yields. So fertilizer costs more to make.

“Fertilizer prices last year were already quite high. They had come down somewhat in the last few months and now are very high again,” Janzen said, “in part because Russia and its ally Belarus are major fertilizer exporters.”

And Russia and Belarus are both under sanctions for the Ukraine invasion.

But those are problems for the next crop. People in parts of the Middle East and North Africa are feeling the effects now.

Fragile situations

“Yemen is a good case in point,” Barrett said. “There’s not a lot of wheat being grown in Yemen. They depend entirely upon wheat imports, and that requires transportation to get there.”

“The spike in global wheat prices plus the spike in global oil prices mean that prices for flour and for bread products in Yemen are already increasing significantly in a place where people really can’t afford to face an even higher cost of feeding their family basic daily rations,” he added.

In 2011, rising bread prices were one of the factors that set off the Arab Spring protests. When people already have grievances with their government, food inflation can tip them over the edge. A lot of places fit that description, according to U.N. World Food Program Chief Economist Arif Husain.

“If you look at Yemen, if you look at Lebanon, if you look at Syria, if you look at South Sudan, if you look at Ethiopia, and I can keep going,” Husain said in an interview with The Associated Press. “These countries are already in trouble because of conflicts.”

On the plus side, spring planting hasn’t started yet in some big wheat-growing countries. Farmers will probably switch some land where they planned to grow corn or soybeans to planting wheat. That should eventually bring the price down.

“That seems to be the main way that these crises are inevitably resolved is by production somewhere else in the world responding,” Janzen said. “We are fortunate that we have a global food system. We have the ability to produce and consume commodities like wheat all around the world.”

It will be months before the markets have a sense of how big the new crop will be, however. Those will be nail-biting months of watching the weather. Experts say, be ready for a wild ride.

Source: Voice of America